Sign inJoin waitlistJoin the waitlist

Benjamin Mixon

Division Chief, Hematology/Oncology · University of Tennessee College of Medicine

Credentials: · · · ·

History

Hematology/Oncology Division · University of Tennessee College of Medicine
Present
University of Tennessee College of Medicine
Present

Vanderbilt University School of Medicine
2008–2009
Pediatrics
University of South Florida
2005–2008
University of South Florida College of Medicine
2001–2005

Research

A novel 33-Gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias
British Journal of Haematology · 2016 · 71 citations
Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia
Cancer Medicine · 2021 · 23 citations
An intrauterine insemination-ready cryopreservation method compared with sperm recovery after conventional freezing and post-thaw processing
Fertility and Sterility · 1997 · 21 citations

KB
Kenneth Burry
2 papers
AT
Angela Thyer
1 paper · 1 as a resident
Ashley Hinson
1 paper
Erin Breese
1 paper
Etan Orgel
1 paper
HM
Hector Monforte
1 paper
Jennifer McNeer
1 paper
JB
Jerry Barbosa
1 paper
JP
Joanna Pierro
1 paper
Laura Drach
1 paper · 1 as a fellow
Michael Burke
1 paper
ME
Michael Eckrich
1 paper · 1 as a fellow

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Site PI · Recruiting · Phase 3
Children's Oncology Group
2020–2029
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032